ASCENTAGE PHARMA GROUP INTERNATIONAL

Contributing Author

Recent Articles by ASCENTAGE PHARMA GROUP INTERNATIONAL

13 hours	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Pricing of Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Proposed Top-Up Placement AAPG GlobeNewswire
Jul-10	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL AAPG GlobeNewswire
Jul-07	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance AAPG GlobeNewswire
Jun-15	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL AAPG GlobeNewswire
Jun-09	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors AAPG GlobeNewswire
May-22	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 AAPG GlobeNewswire